OSRH
OSR Holdings, Inc.0.5536
-0.0238-4.12%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
14.21MP/E (TTM)
-Basic EPS (TTM)
-0.28Dividend Yield
0%Recent Filings
8-K
Vaximm VXM01 license term sheet
OSR Holdings' subsidiary Vaximm AG signed a non-binding term sheet on November 21, 2025, with BCM Europe AG—its largest shareholder—for a potential global license of the VXM01 oral cancer immunotherapy platform. Terms outline $20M upfront and up to $815M in milestones, plus royalty pass-through after BCME recovers any milestone delta from a future pharma partner. Non-binding beyond 120-day exclusivity. Deal hinges on definitive agreement.
10-Q
Q3 FY2025 results
OSR Holdings posted Q3 net sales of $627.7K, down 24% y/y yet gross profit climbed 46% to $261.7K on RMC's shift to a consignment model that slashed cost of sales 43% (derived). Operating loss widened slightly to $3.8M while net loss narrowed to $3.2M, with the net-operating gap driven by $685K other expenses including fair-value changes. Cash swelled to $2.2M on $5.2M financing inflows, against $3.3M operating burn YTD; short-term borrowings hit $1.9M. Business combination closed Feb 2025 via equity swap, no goodwill recorded per ASC 805. Nasdaq bid price lags below $1.00.
8-K
OSRH acquires noninvasive glucose tech
OSR Holdings' subsidiary OSRK signed a share exchange agreement on October 13, 2025, to acquire Woori IO, a South Korea-based developer of needle-free glucose monitoring via near-infrared spectroscopy, for KRW 15 billion (USD 10.6 million). This bolsters OSRH's medical-device portfolio with WORIO's Samsung-backed tech, targeting the $40+ billion global market by 2030, while enabling digital health integrations. Closing awaits approvals, eyed for January 12, 2026. Contingent conversion to OSRH stock hinges on hitting $10 per share within three years.
8-K
8-K
Chardan sues OSR Holdings
Chardan Capital Markets sued OSR Holdings and executive Kuk Hyoun Hwang on September 2, 2025, in New York federal court, demanding about $2,070,000 plus 34,500 shares of deferred equity over previously disclosed SEC matters. The company plans a vigorous defense. This litigation adds uncertainty to operations.
CERO
CERo Therapeutics Holdings, Inc
0.09-0.01
CPMV
Mosaic ImmunoEngineering Inc.
0.40+0.00
OBIO
Orchestra BioMed Holdings, Inc.
4.46+0.16
OCEA
Ocean Biomediacal, Inc.
0.00+0.00
OMER
Omeros Corporation
8.77-0.43
ORKA
Oruka Therapeutics, Inc.
28.94-1.16
OSTX
OS Therapies Incorporated
1.62-0.05
SONN
Sonnet BioTherapeutics Holdings
1.26-1.84
VKTX
Viking Therapeutics, Inc.
35.72-0.43
VXRT
Vaxart, Inc.
0.37+0.01